Alcon to Buy Lensar in Deal Worth Up to $430M

Dow Jones
03-24

By Dean Seal

 

Alcon has agreed to acquire the medical-technology company Lensar in a deal that could be worth up to $430 million.

The eye-care company said Monday that it would pay $14 for each Lensar share in cash, and an additional $2.75 per share based on certain milestones for Lensar's products in 2026 and 2027.

The transaction includes Lensar's ALLY Robotic Cataract Laser Treatment System, its proprietary Streamline software and its legacy laser system, which should benefit Alcon's laser-assisted cataract surgery offering.

The deal is expected to close in mid-to-late 2025, subject to approval from regulators and Lensar's shareholders.

Shares of Lensar were halted at $14.57 in premarket trading.

 

Write to Dean Seal at dean.seal@wsj.com

 

(END) Dow Jones Newswires

March 24, 2025 08:21 ET (12:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10